Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL28322902 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13575793 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL678442 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8089096 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13933092 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL18 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL6159149 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL97 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL474012 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL28323975 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| CN-111724866-B | Automated prediction of biological responses of chemical-information based compounds | 塔塔咨询服务有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | disclosed |
| CN-111712241-B | Sigma-1 receptor agonist systolic blood pressure therapy | 阿纳韦克斯生命科学公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11651838-B2 | Automated prediction of biological response of chemical compounds based on chemical information | TATA CONSULTANCY SERVICES LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | Accencio LLC | 2023-04-13 | — | — | US | disclosed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | disclosed |
| US-20210145964-A1 | STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS | ACADEMISCH MEDISCH CENTRUM (NL) | 2021-05-20 | — | — | US | disclosed |
| EP-3712897-A1 | AUTOMATED PREDICTION OF BIOLOGICAL RESPONSE OF CHEMICAL COMPOUNDS BASED ON CHEMICAL INFORMATION | Tata Consultancy Services Limited (IN) | 2020-09-23 | — | — | EP | disclosed |
| CN-108743955-A | One kind being used for essential hypertension elastomer subdermal implantation stick | 吕鹏威 | 2018-11-06 | — | — | CN | disclosed |
| CN-101590238-A | The compositions and the purposes that contain angiotensin-convertion enzyme inhibitor, Ta Ting and folic acid | BEIJNG AOSA MEDICAL RES CT INC (CN) | 2009-12-02 | — | — | CN | disclosed |
| CN-1665500-A | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL MYERS SQUIBB CO (US) | 2005-09-07 | — | — | CN | disclosed |
| US-5929251-A | Process for the preparation of carboxylic acid succinimidyl esters | DSM FINE CHEMICALS AUSTRIA GMBH (AU) | 1999-07-27 | — | — | US | disclosed |
| US-5734064-A | Process for the preparation of carboxylic acid succinimidyl esters | DSM CHEMIE LINZ GMBH (AT) | 1998-03-31 | — | — | US | disclosed |
| EP-0799824-A1 | Process for the preparation of carboxylic acid succinimidyl esters | DSM Chemie Linz GmbH (AT) | 1997-10-08 | — | — | EP | disclosed |
| US-5543155-A | AMMONIUM METHACRYLATE COPOLYMER | EGIS GYOGYSZERGYAR RT. (HU) | 1996-08-06 | — | — | US | disclosed |
| CN-1034312-A | With angiotensin converting enzyme (ACE) inhibitor prevent and treat anxiety method, | SQUIBB & SONS INC (US) | 1989-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | ACE 1/4885LMNA 2391/4885SMN1; SMN2 1792/4885 |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | ACE, ACE2, TMPRSS2 | ACE 1/4885LMNA 1920/4885SMN1; SMN2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.